loading page

Allergen Immunotherapy in Atopic Dermatitis: light and shadow in children.
  • +7
  • lucia Caminiti,
  • ILENIA PANASITI,
  • Massimo Landi,
  • Maria De Filippo,
  • Roberta Olcese,
  • Giorgio Ciprandi,
  • Vernich Mario ,
  • Carelli Francesco,
  • Martina Votto,
  • Salvatore Barberi
lucia Caminiti
University of Messina

Corresponding Author:lucycaminiti@yahoo.it

Author Profile
ILENIA PANASITI
Universita degli Studi di Messina
Author Profile
Massimo Landi
National Pediatric Healthcare System
Author Profile
Maria De Filippo
University Hospital of Montpellier, Arnaud de Villeneuve
Author Profile
Roberta Olcese
Istituto Giannina Gaslini
Author Profile
Giorgio Ciprandi
2 Allergy and Respiratory Diseases Clinic
Author Profile
Vernich Mario
ASST-Rhodense, RHO Milan
Author Profile
Carelli Francesco
Azienza Ospedaliera Universitaria, Policlinic Giovanni XXIII
Author Profile
Martina Votto
Fondazione IRCCS Policlinico San Matteo
Author Profile
Salvatore Barberi
Ospedale San Paolo, Milano
Author Profile

Abstract

Atopic dermatitis (AD) is a chronic remitting-relapsing inflammatory skin disorder. Due to the multifactorial pathogenesis, there are numerous therapeutic management approaches, mainly based on symptomatic treatments. In recent years Allergen Immunotherapy (AIT) has been progressively advanced as targeted disease-modifying treatment of allergic disease. The most recent guideline from the American Academy of Dermatology concludes that data available do not support its use in AD. The Joint Task Force and The European Academy of Dermatology suggest that clinicians can consider AIT treatment in selected patients characterized by aeroallergen sensitization, prevalently HDM, severe AD, clinical exacerbation after exposure to the causative allergen. Nevertheless, its role in AD is still under debate, especially in children.
07 Aug 2020Submitted to Pediatric Allergy and Immunology
23 Sep 2020Review(s) Completed, Editorial Evaluation Pending
23 Sep 2020Editorial Decision: Revise Minor
24 Sep 20201st Revision Received
26 Sep 2020Review(s) Completed, Editorial Evaluation Pending
28 Sep 2020Editorial Decision: Revise Major
30 Sep 20202nd Revision Received
30 Sep 2020Review(s) Completed, Editorial Evaluation Pending
30 Sep 2020Editorial Decision: Accept
Nov 2020Published in Pediatric Allergy and Immunology volume 31 issue S26 on pages 46-48. 10.1111/pai.13390